Nakanishi Inc. (JP:7716)
:7716
Top Page
Nakanishi
(7716)
Select Model
Select Model
Rating:63Neutral
Price Target:
¥3,010.00
▲(51.94% Upside)
Action:ReiteratedDate:02/18/26
The score is driven primarily by solid underlying financial strength (strong balance sheet and cash generation) but is held back by the 2025 net loss and valuation uncertainty (negative P/E). Technicals remain in an uptrend, yet extreme overbought signals reduce the near-term technical score.
Positive Factors
Balance sheet strength
The balance sheet shows substantial equity and moderate leverage (debt/equity ~0.23 in 2025). That financial position provides flexibility to fund R&D, sustain distributor support, and absorb cyclicality without immediate equity raising, supporting long-term operational resilience.
Negative Factors
2025 net loss / earnings volatility
A net loss in 2025 despite positive operating profit signals below-the-line pressures (non-operating items, taxes or one-offs) that reduce reported earnings stability. Persistent volatility in net income complicates dividend policy, investor confidence and long-term planning.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
The balance sheet shows substantial equity and moderate leverage (debt/equity ~0.23 in 2025). That financial position provides flexibility to fund R&D, sustain distributor support, and absorb cyclicality without immediate equity raising, supporting long-term operational resilience.
Read all positive factors
Nakanishi (7716) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥234.08B
Dividend Yield2.66%
Average Volume (3M)128.45K
Price to Earnings (P/E)―
Beta (1Y)0.72
Revenue Growth5.43%
EPS Growth-20.67%
CountryJP
Employees2,180
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-102.55
Shares Outstanding92,218,200
10 Day Avg. Volume125,180
30 Day Avg. Volume128,446
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)1.45
Price to Sales (P/S)2.04
P/FCF Ratio13.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥3,500.00Price Target Upside76.68% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)134.21
Revenue Forecast (FY)¥87.73B
Nakanishi Business Overview & Revenue Model
Company Description
Nakanishi Inc. manufactures and sells dental, industrial, and medical products worldwide. The company offers turbines; clinical micromotors; contra-angles; and built-in, mobile dentistry, oral hygiene, endodontic, surgical, dental laboratory, and ...
How the Company Makes Money
Nakanishi makes money primarily by selling precision rotary equipment and the associated consumables/accessories used with that equipment across its medical and industrial segments. In its dental/medical business, revenue is generated from sales o...
Nakanishi Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
78
Positive
Cash Flow
74
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 77.67B | 81.18B | 77.04B | 59.69B | 48.67B | 44.86B |
| Gross Profit | 43.07B | 44.59B | 40.39B | 34.15B | 30.39B | 26.60B |
| EBITDA | 19.80B | 19.90B | 20.46B | 17.71B | 17.49B | 15.61B |
| Net Income | 5.06B | -2.40B | 8.58B | 22.80B | 12.47B | 10.10B |
Balance Sheet | ||||||
| Total Assets | 153.77B | 160.16B | 158.30B | 140.77B | 102.64B | 94.46B |
| Cash, Cash Equivalents and Short-Term Investments | 47.81B | 62.80B | 47.11B | 32.65B | 38.19B | 41.75B |
| Total Debt | 20.57B | 26.77B | 18.73B | 11.67B | 480.80M | 100.00M |
| Total Liabilities | 36.47B | 46.08B | 37.10B | 27.60B | 11.61B | 11.54B |
| Stockholders Equity | 117.30B | 114.07B | 121.19B | 113.15B | 91.02B | 82.92B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 12.26B | 10.48B | 2.93B | 4.29B | 10.20B |
| Operating Cash Flow | 0.00 | 16.65B | 15.30B | 8.56B | 7.76B | 11.97B |
| Investing Cash Flow | 0.00 | -8.68B | -7.94B | -19.15B | -6.31B | -4.15B |
| Financing Cash Flow | 0.00 | 679.15M | 598.51M | 3.41B | -6.11B | -3.97B |
Nakanishi Technical Analysis
Positive
1981.00
Price Trends
2448.60
Positive
2214.54
Positive
2094.79
Positive
Market Momentum
91.38
Positive
55.79
Neutral
51.09
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7716, the sentiment is Positive. The current price of 1981 is below the 20-day moving average (MA) of 2725.30, below the 50-day MA of 2448.60, and below the 200-day MA of 2094.79, indicating a neutral trend. The MACD of 91.38 indicates Positive momentum. The RSI at 55.79 is Neutral, neither overbought nor oversold. The STOCH value of 51.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:7716.
Nakanishi Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | ¥144.13B | 18.72 | ― | 2.73% | 5.10% | -26.13% | |
69 Neutral | ¥59.09B | 19.92 | ― | 2.83% | 3.69% | 1.86% | |
68 Neutral | ¥870.79B | 24.33 | 11.64% | 0.82% | 13.53% | -7.39% | |
63 Neutral | ¥234.08B | -69.02 | -2.06% | 2.66% | 5.43% | -20.67% | |
60 Neutral | ¥1.55T | 38.56 | 11.34% | 1.01% | 0.42% | 34.76% | |
54 Neutral | ¥240.89B | 5.59 | 4.38% | 2.03% | 6.04% | 733.13% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
JP:7716
Nakanishi
2,773.00
612.72
28.36%
JP:7747
Asahi Intecc Co
3,282.00
887.74
37.08%
JP:8086
Nipro
1,507.00
146.23
10.75%
JP:7733
Olympus
1,408.00
-592.47
-29.62%
JP:7730
Mani, Inc.
1,505.00
173.37
13.02%
JP:7979
Shofu Inc.
1,698.00
-343.68
-16.83%
Nakanishi Corporate Events
Nakanishi Buys U.S. Neurosurgical Firms to Boost Surgical Business and North American Manufacturing
Mar 5, 2026
Nakanishi Inc.’s U.S. unit NSK America Corp. will acquire all shares of neurosurgical device maker Acra Cut, Inc. and precision manufacturer Intech, Inc., turning them into second-tier subsidiaries. The transaction, conducted under a confide...
Nakanishi Raises 2026 Earnings Outlook on U.S. Medical Device Acquisitions
Mar 5, 2026
Nakanishi Inc. has revised upward its consolidated financial forecasts for the first half and full year ending December 31, 2026, reflecting stronger expected performance. The company now projects modest increases in net sales, operating profit, o...
Nakanishi Delays Start of Board-Approved Share Buyback Program
Mar 2, 2026
Nakanishi Inc. reported that, despite having board approval to repurchase up to 1.5 million common shares for a maximum of JPY 2.5 billion between February 13 and December 30, 2026, it conducted no buybacks during the initial period from February ...
Nakanishi Maintains Board Lineup, Adds New Outside Auditor for 2026
Feb 12, 2026
Nakanishi Inc. has announced a slate of six director candidates, all standing for reappointment as their current terms expire, to be voted on at the 74th Annual General Meeting of Shareholders on March 30, 2026. The proposed board lineup maintains...
Nakanishi Launches ¥2.5 Billion Share Buyback to Boost Shareholder Returns
Feb 12, 2026
Nakanishi Inc. has authorized a share repurchase program under Japan’s Companies Act, approving the buyback of up to 1.5 million common shares, or about 1.81% of its outstanding shares excluding treasury stock. The maximum total cost of the ...
Nakanishi Takes ¥13.8 Billion Goodwill Hit as DCI Tariffs Drag, Despite Beating FY2025 Forecasts
Feb 12, 2026
Nakanishi Inc. reported that net sales, EBITDA, operating profit and ordinary profit for the year ended December 31, 2025 exceeded earlier forecasts, supported by steady performance in its Dental, DCI, Surgical and Industrial segments and a weaker...
Nakanishi Swings to Loss but Lifts Dividend and Forecasts Earnings Rebound
Feb 12, 2026
Nakanishi reported consolidated net sales of ¥81.2 billion for fiscal 2025, up 5.4% year on year, while operating and ordinary income slipped 3.5% and 2.0% respectively. The company swung to a net loss attributable to owners of ¥2.4 bill...
Nakanishi Completes ¥2.9 Billion Share Buyback Below Authorized Limit
Jan 5, 2026
Nakanishi Inc. has announced the status and completion of a share repurchase program authorized by its board of directors on February 12, 2025, under the Companies Act of Japan. Against a maximum authorization of 2,000,000 shares and up to ¥3...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.